Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
Date:8/8/2011

NEW YORK, Aug. 8, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the second quarter ended June 30, 2011.

At June 30, 2011, the Company had cash, cash equivalents, interest receivable and investment securities of $52.5 million, as compared to $28.5 million at December 31, 2010. In May 2011, the Company completed an underwritten registered offering of common stock, which provided proceeds to the Company of approximately $30.8 million, net of underwriting discounts and offering expenses of approximately $2.2 million.  

The net loss for the second quarter ended June 30, 2011 was $3.1 million, or $0.05 per share, compared to a net loss of $5.2 million, or $0.09 per share, for the second quarter in 2010, representing a decrease in net loss of $2.1 million.  The three months ended June 30, 2011 included license revenue of $5.0 million related to a milestone payment from the Company's Japanese partner for Zerenex (ferric citrate), Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., for their commencement of a Phase 3 clinical program of ferric citrate in Japan.  Other research and development expenses, for the second quarter ended June 30, 2011, increased by $3.2 million, as compared to the second quarter of 2010, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the second quarter ended June 30, 2011, included $0.5 million of non-cash compensation expense related to equity incentive grants.

The net loss for the six months ended June 30, 2011 was $9.5 million, or $0.15 per share, compared to a net loss of $
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
3. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
4. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
7. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
10. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
11. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 Research and Markets ... "Radiology Information Systems Market by Type, Deployment Mode, ... Forecast to 2019" report to their offering. ... estimated at $501.1 Million 2014, and is projected to ... 7.6% from 2014 to 2019. The ...
(Date:9/3/2015)... -- The findings of a year-long investigation conducted by NBC ... handling of its Recovery IVC filter product ... part one of the series revealed that ... fatalities, have been associated with the Recovery device. NBC ... Bard in 2004 which linked the Recovery IVC filter ...
(Date:9/3/2015)... DUBLIN , Sep. 03, 2015 ... announced the addition of the "Investigation Report on ... As air pollution worsens, the incidence of ... size of relevant drugs. Bromhexine, a semisynthetic derivative of ... of chronic bronchitis and asthma associated with viscid or ...
Breaking Medicine Technology:Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 2Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 3IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3China Bromhexine Market Report 2015-2019 2
... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), ... (ESI) announced the selection of its,disinfectant, EnviroTru(TM) ... Authority (Metro). EnviroTru(TM) is a multi-purpose ... and also meets EPA requirements for,Toxicity Category ...
... Presented at Anti-Angiogenesis Conference Shows R84, the Selective Human ... Affitech, Is Equivalent to Avastin in Inhibiting Growth of Established ... Tumors in a Preclinical Breast Cancer Model -- ... a Potential Clinical Candidate --, BOSTON and TUSTIN, Calif., ...
Cached Medicine Technology:Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 2New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 3New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 4New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 5
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... William Mattar ... William Mattar, Esq. believes this does not stop at any certain demographic or segment ... its newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning ...
(Date:9/3/2015)... ... 03, 2015 , ... Topical BioMedics, Inc., hosted Amsterdam resident ... six-month, 10,000 mile journey from Santiago, Chile to Times Square and then Rhinebeck, ... Las Americas” project—Max crossed six countries in 168 days on his 39-year-old Moto ...
(Date:9/3/2015)... ... September 03, 2015 , ... Silverado next week lays ... Columbine Drive in Bellingham, Washington. Silverado Bellingham, a 41,000 square foot, single-story community, ... serve up to 80 people living with Alzheimer’s, dementia and other memory-impairing conditions. ...
(Date:9/3/2015)... ... September 03, 2015 , ... RealtyShares , the online ... institutional investors to real estate investment opportunities nationwide, today announced that it is ... investors and sponsoring real estate companies. , These products typically involve ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... Intellicure, Inc., in its Annual Inc. 5000 list of fastest-growing private companies ... "only a tiny fraction of the nation's companies have demonstrated such remarkably consistent ...
Breaking Medicine News(10 mins):Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2
... and Caitlin Mason from Queens University, Canada has reported in ... national surveys which reported the obesity// and overweight in Canadian ... between 1985 to 2003. The study showed an increasing trend ... a shift in BMI index from Class II to Class ...
... like that of viral flu are spreading across Delhi with ... a minimum of 0.2 degrees Celsius (7 degrees below normal) ... reached 11.6 degrees //(five degree above normal) on 17 January ... the weather change. ,‘There is a sudden ...
... approved the drug for use to treat the cancer multiple ... the Department of Health and Ageing. It is available through ... is to go to the PBS," as said by the ... the drug was originally used in Australia in the late ...
... died in Singapore a few days after the operation, and ... is reported to have suffered from a heart attack while ... transplant surgeon K.C. Tan. ,The recipient, a ... enough to go home. Tan said the donor was put ...
... of Science throws light on cells that could prevent ... in the February issue of Nature Neuroscience. ... led the study, //which might have important implication in ... The researchers say that immune cells play a key ...
... 39-year-old Mogjan Azari, a dentist who was jailed for one ... and is banned from practicisig. Azari allowed her boyfriend Omid ... devastating consequences. ,Mazaheri practiced on Azari's patients without ... days. On one occasion he broke a syringe in a ...
Cached Medicine News:Health News:Weizmann Institute of Science says Immune Cells Could Help Maintain Brain Function 2
Farabeuf periosteal elevators....
OHL periosteal elevator, 19 cm, 7-1/2"....
Steinhauser periosteal elevator....
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Medicine Products: